Auris Medical (EARS) Shares Down 18.2%

Share on StockTwits

Auris Medical Holding AG (NASDAQ:EARS)’s share price was down 18.2% during trading on Monday . The stock traded as low as $0.35 and last traded at $0.36. Approximately 4,817,269 shares traded hands during mid-day trading, an increase of 161% from the average daily volume of 1,844,024 shares. The stock had previously closed at $0.44.

A number of equities analysts have recently issued reports on EARS shares. Roth Capital started coverage on Auris Medical in a research report on Thursday, December 20th. They set a “buy” rating and a $5.00 price target on the stock. ValuEngine raised Auris Medical from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research downgraded Auris Medical from a “buy” rating to a “hold” rating in a research report on Monday, January 21st.

The stock has a market capitalization of $14.74 million, a PE ratio of -0.06 and a beta of -0.57.

Auris Medical (NASDAQ:EARS) last posted its quarterly earnings results on Thursday, November 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). As a group, equities analysts forecast that Auris Medical Holding AG will post -0.42 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4144453/auris-medical-ears-shares-down-18-2.html.

About Auris Medical (NASDAQ:EARS)

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Price-Sales Ratio

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Cuts Shaftesbury  Price Target to GBX 910
Barclays Cuts Shaftesbury Price Target to GBX 910
Moneysupermarket.Com Group  PT Raised to GBX 325 at Barclays
Moneysupermarket.Com Group PT Raised to GBX 325 at Barclays
Novanta  Raised to “Buy” at Zacks Investment Research
Novanta Raised to “Buy” at Zacks Investment Research
Thomson Reuters  to Release Earnings on Tuesday
Thomson Reuters to Release Earnings on Tuesday
Workiva  Set to Announce Quarterly Earnings on Wednesday
Workiva Set to Announce Quarterly Earnings on Wednesday
Insight Enterprises, Inc. to Post Q1 2019 Earnings of $0.96 Per Share, B. Riley Forecasts
Insight Enterprises, Inc. to Post Q1 2019 Earnings of $0.96 Per Share, B. Riley Forecasts


Leave a Reply

© 2006-2019 Ticker Report